Document is current

Any future updates will be listed below

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P83

Published Online: 2015-11-04

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark